The EPS beat is mechanical given the tiny base and share count changes (40.6M shares vs 9.4M YoY). The $11M debt financing and GPO agreements for REZENOPY™ are the real catalysts — monitor for REZENOPY™ launch (sales force starts June 1, 2026) and subsequent quarterly revenue ramp. Cash burn of ~$3.1M/quarter suggests the $3.5M cash balance plus $11M debt provides ~4-5 quarters of runway. The stock is a binary story stock; watch for prescription trends and institutional adoption data.
Price Chart
Executive Summary
Scienture Holdings reported Q1 2026 revenue of ~$56K (up 449% YoY from ~$10K) and gross margin expansion to 95.6%, driven by initial Arbli™ product orders. Net loss widened to ~$3.4M from ~$3.1M, but EPS of -$0.08 beat consensus of -$0.23 by 65%. The company secured $11M in non-dilutive debt financing and advanced commercial GPO agreements for REZENOPY™ covering ~60% of the U.S. institutional market. Despite the revenue growth from a tiny base, the company remains pre-revenue at scale with a $16M market cap and an accumulated deficit of ~$84M.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of ~$56K, up 449% YoY from ~$10K
- Gross profit of ~$54K vs ~$673 YoY; gross margin 95.6% vs 6.6%
- Net loss of ~$3.4M vs ~$3.1M YoY; EPS -$0.08 beat consensus -$0.23 by 65%
- Secured $11.0M in non-dilutive debt financing
- GPO agreements for REZENOPY™ covering ~5,000 institutions (~60% of U.S. institutional market)
- Third USPTO patent for Arbli™ extending exclusivity through 2041
- Cash & equivalents of ~$3.5M at March 31, 2026, down from ~$6.7M at Dec 31, 2025
- Accumulated deficit of ~$84.0M; total stockholders' equity ~$66.8M
Financial Impact
Revenue of ~$56K (tiny base) with gross margin expansion to 95.6%; net loss widened to ~$3.4M; EPS beat of 65% on a -$0.08 actual vs -$0.23 consensus
Risk Factors
- Pre-revenue at scale with only ~$56K quarterly revenue; commercialization of Arbli™ and REZENOPY™ may not achieve meaningful penetration
- Cash burn of ~$3.1M/quarter; $3.5M cash + $11M debt provides limited runway (~4-5 quarters) before needing additional capital
- Accumulated deficit of ~$84M; no path to profitability guided before 2027
- Dependence on successful launch of REZENOPY™ (naloxone nasal spray) in a competitive opioid overdose reversal market
- Nasdaq continued listing risk given $16M market cap and potential non-compliance with minimum bid price or market value of listed securities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025062 |
| Document: form8-k.htm | 0001493152-26-025062 |
| Document: 0001493152-26-025062-index-headers.html | 0001493152-26-025062 |
| Document: 0001493152-26-025062-index.html | 0001493152-26-025062 |
| Document: 0001493152-26-025062.txt | 0001493152-26-025062 |
| 8-K Data (Synthetic) | 0001493152-26-025062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.77 | awaiting T+5 | — | $3.23 (+16.61%) |
Oct 19, 2026 8d ago | 8-K | $3.05 $3.23 | ▲ +5.90% | ▲ +5.82% | $3.23 (+5.90%) |
Oct 13, 2026 14d ago | Press Release | $3.24 $3.05 | ▲ +5.86% | ▲ +4.71% | $3.23 (+0.31%) |
Oct 7, 2026 20d ago | 8-K | $3.86 $3.38 | ▼ −12.44% | ▼ −12.16% | $3.23 (−16.32%) |
May 29, 2026 21w ago | 8-K | $0.3960 $0.3600 | ▼ −9.09% | ▼ −6.34% | $3.23 (+715.66%) |
May 22, 2026 22w ago | 8-K | $0.4000 $0.3910 | ▼ −2.25% | ▼ −3.46% | $3.23 (+707.50%) |
May 18, 2026 23w ago | Press Release | $0.3940 $0.4000 | ▲ +1.52% | ▼ −0.10% | $3.23 (+719.80%) |
May 5, 2026 25w ago | 8-K | $0.3910 $0.3980 | ▲ +1.79% | ▲ +0.66% | $3.23 (+726.09%) |
Apr 30, 2026 25w ago | 10-K/A | $0.4010 $0.4000 | ▲ +0.25% | ▲ +2.60% | $3.23 (−705.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers